Atea Pharmaceuticals (NASDAQ:AVIR) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Atea Pharmaceuticals (NASDAQ:AVIR) released its quarterly earnings data on Wednesday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.15, FiscalAI reports.

Here are the key takeaways from Atea Pharmaceuticals’ conference call:

• C-BEYOND met its primary and secondary endpoints: bemnifosbuvir/ruzasvir achieved a 93.9% SVR rate versus 94.8% for EPCLUSA, demonstrating statistical non-inferiority in a challenging real-world HCV population. Non-cirrhotic patients received an eight-week regimen versus 12 weeks for EPCLUSA, with comparable safety.
• C-FORWARD is fully enrolled with more than 880 patients, and top-line results are expected in early Q1 2027. Pending positive results, Atea expects to submit a U.S. NDA in Q2 2027, although approval and timing remain uncertain.
• Management believes the regimen’s potential advantages—including shorter treatment duration, limited drug-drug interactions, no food effect, and a protease-inhibitor-free composition—could support uptake in poly-medicated and adherence-challenged patients. Atea projects peak annual U.S. net revenue of more than $700 million and a relatively short path to profitability after a targeted mid-2028 launch.
• Atea initiated a Phase I study of AT-587 for hepatitis E, a disease with no approved therapy, and reported completion of the first cohort. The company is targeting proof-of-concept data in 2027, but the program remains at an early clinical stage.
• Atea ended the quarter with $219.5 million in cash and marketable securities and expects its cash runway to extend through 2027. Spending will remain focused primarily on completing the HCV program, regulatory preparation, commercial readiness, and hepatitis E development.

Atea Pharmaceuticals Stock Performance

Shares of NASDAQ:AVIR traded up $0.01 during mid-day trading on Wednesday, hitting $5.06. 292,168 shares of the company traded hands, compared to its average volume of 422,951. The firm’s 50 day simple moving average is $4.65 and its 200 day simple moving average is $4.90. The firm has a market cap of $404.94 million, a P/E ratio of -2.40 and a beta of 0.30. Atea Pharmaceuticals has a 52-week low of $2.78 and a 52-week high of $6.45.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Institutional Trading of Atea Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Opaleye Management Inc. purchased a new stake in shares of Atea Pharmaceuticals during the fourth quarter valued at approximately $642,000. Millennium Management LLC boosted its stake in shares of Atea Pharmaceuticals by 43.3% in the fourth quarter. Millennium Management LLC now owns 698,156 shares of the company’s stock valued at $2,492,000 after purchasing an additional 210,933 shares during the period. Bridgeway Capital Management LLC grew its holdings in Atea Pharmaceuticals by 3.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 148,400 shares of the company’s stock valued at $530,000 after purchasing an additional 5,300 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Atea Pharmaceuticals during the 4th quarter valued at $164,000. Finally, Jump Financial LLC increased its stake in Atea Pharmaceuticals by 36.5% during the 4th quarter. Jump Financial LLC now owns 19,113 shares of the company’s stock worth $68,000 after buying an additional 5,106 shares during the period. Institutional investors and hedge funds own 86.67% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.